Boston Scientific Corporation (BSX) Covered Calls

Boston Scientific Corporation covered calls Boston Scientific Corporation is a leading global developer and manufacturer of medical devices used in a broad range of interventional medical specialties. The company provides innovative solutions for cardiovascular, endoscopy, urology, and neuromodulation procedures. Its products are designed to diagnose and treat complex diseases including heart rhythm disorders, chronic pain, and digestive conditions, helping healthcare providers improve patient outcomes and reduce healthcare costs.

You can sell covered calls on Boston Scientific Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BSX (prices last updated Thu 11:15 AM ET):

Boston Scientific Corporation (BSX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
76.05 -0.24 76.03 76.05 2.6M 41 113
Covered Calls For Boston Scientific Corporation (BSX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 76 0.55 75.50 0.7% 128%
Mar 20 75 2.95 73.10 2.6% 31.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Boston Scientific Corporation (BSX) is a global leader in the medical technology industry, specializing in less-invasive medical devices that address a wide variety of clinical needs. The company operates through a diversified portfolio focused on high-growth medical specialties, utilizing engineering and clinical data to drive innovation in surgical and interventional care.

Core Business and Products

  1. Cardiovascular: This is the company’s largest segment, featuring the WATCHMAN left atrial appendage closure device for stroke prevention and the Farapulse pulsed-field ablation system for treating atrial fibrillation. It also includes interventional cardiology products like drug-eluting stents and coronary imaging tools.
  2. Endoscopy and Urology: The company provides a vast array of devices for diagnosing and treating gastrointestinal and pulmonary conditions, including the AXIOS stent. In urology, it offers solutions for kidney stones, prostate health, and pelvic floor disorders, bolstered by the acquisition of specialized laser and surgical technologies.
  3. Neuromodulation: This segment focuses on implantable technologies to manage chronic pain and neurological movement disorders. Its deep brain stimulation and spinal cord stimulation systems provide therapeutic alternatives for patients who do not respond well to traditional pharmaceutical treatments.

Competitive Landscape

The medical device market is highly competitive and regulated. In the cardiovascular and electrophysiology sectors, the company competes directly with Medtronic, Abbott, and Johnson & Johnson. In the surgical and endoscopy fields, it faces competition from Stryker and Intuitive Surgical. Other notable rivals in specialized niches include Edwards Lifesciences and Becton Dickinson. The company often differentiates itself through aggressive research and development and the acquisition of emerging biotech firms to expand its peripheral vascular portfolio.

Strategic Outlook and Innovation

The company is focused on sustaining its category leadership by expanding into high-growth adjacencies within its core segments. Innovation efforts are currently centered on the global rollout of pulsed-field ablation technology, which is expected to redefine the standard of care for heart rhythm disorders. Management is also prioritizing digital health integration, using data analytics to enhance the performance of its implantable devices and improve procedural efficiency for physicians. Strategic capital allocation remains a priority, with an emphasis on acquiring disruptive technologies in urology and oncology to diversify revenue streams. By investing in global supply chain resilience and expanding its presence in emerging markets, the company aims to maintain its trajectory of above-market growth while addressing the evolving needs of an aging global population.